Literature DB >> 19165178

Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.

Sandro Rossetti1, Vickie J Kubly, Mark B Consugar, Katharina Hopp, Sushmita Roy, Sharon W Horsley, Dominique Chauveau, Lesley Rees, T Martin Barratt, William G van't Hoff, Patrick Niaudet, W Patrick Niaudet, Vicente E Torres, Peter C Harris.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) caused by mutations in PKD1 is significantly more severe than PKD2. Typically, ADPKD presents in adulthood but is rarely diagnosed in utero with enlarged, echogenic kidneys. Somatic mutations are thought crucial for cyst development, but gene dosage is also important since animal models with hypomorphic alleles develop cysts, but are viable as homozygotes. We screened for mutations in PKD1 and PKD2 in two consanguineous families and found PKD1 missense variants predicted to be pathogenic. In one family, two siblings homozygous for R3277C developed end stage renal disease at ages 75 and 62 years, while six heterozygotes had few cysts. In the other family, the father and two children with moderate to severe disease were homozygous for N3188S. In both families homozygous disease was associated with small cysts of relatively uniform size while marked cyst heterogeneity is typical of ADPKD. In another family, one patient diagnosed in childhood was found to be a compound heterozygote for the PKD1 variants R3105W and R2765C. All three families had evidence of developmental defects of the collecting system. Three additional ADPKD families with in utero onset had a truncating mutation in trans with either R3277C or R2765C. These cases suggest the presence of incompletely penetrant PKD1 alleles. The alleles alone may result in mild cystic disease; two such alleles cause typical to severe disease; and, in combination with an inactivating allele, are associated with early onset disease. Our study indicates that the dosage of functional PKD1 protein may be critical for cyst initiation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165178      PMCID: PMC2813773          DOI: 10.1038/ki.2008.686

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  47 in total

1.  PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein.

Authors:  T Mochizuki; G Wu; T Hayashi; S L Xenophontos; B Veldhuisen; J J Saris; D M Reynolds; Y Cai; P A Gabow; A Pierides; W J Kimberling; M H Breuning; C C Deltas; D J Peters; S Somlo
Journal:  Science       Date:  1996-05-31       Impact factor: 47.728

2.  Perinatal deaths in a family with autosomal dominant polycystic kidney disease and a PKD2 mutation.

Authors:  Carsten Bergmann; Nadina Ortiz Brüchle; Valeska Frank; Helga Rehder; Klaus Zerres
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

3.  Identification of mutations in the duplicated region of the polycystic kidney disease 1 gene (PKD1) by a novel approach.

Authors:  B Peral; V Gamble; C Strong; A C Ong; J Sloane-Stanley; K Zerres; C G Winearls; P C Harris
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.

Authors:  F Qian; T J Watnick; L F Onuchic; G G Germino
Journal:  Cell       Date:  1996-12-13       Impact factor: 41.582

5.  Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.

Authors:  Mark B Consugar; Wai C Wong; Patrick A Lundquist; Sandro Rossetti; Vickie J Kubly; Denise L Walker; Laureano J Rangel; Richard Aspinwall; W Patrick Niaudet; Seza Ozen; Albert David; Milen Velinov; Eric J Bergstralh; Kyongtae T Bae; Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Julian R Sampson; Brian D Dawson; Peter C Harris
Journal:  Kidney Int       Date:  2008-09-24       Impact factor: 10.612

6.  Evidence for a third genetic locus for autosomal dominant polycystic kidney disease.

Authors:  M C Daoust; D M Reynolds; D G Bichet; S Somlo
Journal:  Genomics       Date:  1995-02-10       Impact factor: 5.736

7.  A stable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1 (PKD1).

Authors:  B Peral; A C Ong; J L San Millán; V Gamble; L Rees; P C Harris
Journal:  Hum Mol Genet       Date:  1996-04       Impact factor: 6.150

8.  Screening the 3' region of the polycystic kidney disease 1 (PKD1) gene reveals six novel mutations.

Authors:  B Peral; J L San Millán; A C Ong; V Gamble; C J Ward; C Strong; P C Harris
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

9.  Anticipation of age at renal death in autosomal dominant polycystic kidney disease (ADPKD)?

Authors:  S Geberth; E Ritz; M Zeier; E Stier
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

10.  Autosomal dominant polycystic kidney disease in the fetus.

Authors:  J Michaud; P Russo; A Grignon; L Dallaire; D Bichet; D Rosenblatt; E Lamothe; M Lambert
Journal:  Am J Med Genet       Date:  1994-07-01
View more
  123 in total

1.  Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

Authors:  G Canaud; B Knebelmann; P C Harris; F Vrtovsnik; J-M Correas; N Pallet; C M Heyer; E Letavernier; F Bienaimé; E Thervet; F Martinez; F Terzi; C Legendre
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

2.  B9D1 is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion analysis.

Authors:  Katharina Hopp; Christina M Heyer; Cynthia J Hommerding; Susan A Henke; Jamie L Sundsbak; Shail Patel; Priyanka Patel; Mark B Consugar; Peter G Czarnecki; Troy J Gliem; Vicente E Torres; Sandro Rossetti; Peter C Harris
Journal:  Hum Mol Genet       Date:  2011-04-14       Impact factor: 6.150

Review 3.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

4.  High-resolution melt as a screening method in autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Grazia Maria Virzì; Alice Bruson; Valentina Corradi; Fiorella Gastaldon; Massimo de Cal; Marta Donà; Dinna N Cruz; Maurizio Clementi; Claudio Ronco
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

Review 5.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

Review 6.  Diagnosis and management of childhood polycystic kidney disease.

Authors:  William E Sweeney; Ellis D Avner
Journal:  Pediatr Nephrol       Date:  2010-10-29       Impact factor: 3.714

7.  Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models.

Authors:  Rory J Olson; Katharina Hopp; Harrison Wells; Jessica M Smith; Jessica Furtado; Megan M Constans; Diana L Escobar; Aron M Geurts; Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2019-08-19       Impact factor: 10.121

Review 8.  Molecular diagnostics for autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

9.  Type of PKD1 mutation influences renal outcome in ADPKD.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Jian-Min Chen; Maryvonne Hourmant; Marie-Pascale Morin; Régine Perrichot; Christophe Charasse; Bassem Whebe; Eric Renaudineau; Philippe Jousset; Marie-Paule Guillodo; Anne Grall-Jezequel; Philippe Saliou; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

10.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.